Annals of Oncology Advance Access published online on September 15, 2006
Annals of Oncology, doi:10.1093/annonc/mdl287
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
* To whom correspondence should be addressed. Background: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer. Methods: Studies evaluating survival and TTF-1 in lung cancer patients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated. Results: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%-70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41-1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29-0.95). Conclusion: TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.
Received April 3, 2006
Revised June 30, 2006
Accepted July 3, 2006
original article
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis
T. Berghmans 1 *, M. Paesmans 2, C. Mascaux 1, B. Martin 1, A.-P. Meert 1, A. Haller 3, J.-J. Lafitte 4, and J.-P. Sculier 1
2 Data Centre, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
3 Department of Pathology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
4 Chest Department, Centre Hospitalier Universitaire Calmette, Lille, France
T. Berghmans, E-mail: thierry.berghmans{at}bordet.be
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
V. K. Anagnostou, K. N. Syrigos, G. Bepler, R. J. Homer, and D. L. Rimm Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma J. Clin. Oncol., January 10, 2009; 27(2): 271 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Sculier Prognostic Factors and Implications of Positron Emission Tomography ASCO Educational Book, January 1, 2009; 2009(1): 469 - 472. [Abstract] [Full Text] [PDF] |
||||

